Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VP015
- Development stage
- Discontinued
- Lead developer
- Vasogen
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal
01
Overview
VP015 is a preclinical drug candidate developed by Vasogen Inc. as part of its proprietary 'VP series' of anti-inflammatory therapies. The drug is based on a platform of synthetic three-dimensional phospholipid-based structures (microparticles) designed to modulate the immune system by regulating cytokine levels. Specifically, VP015 has been shown to increase the concentration of the anti-inflammatory cytokine interleukin-4 (IL-4) while simultaneously decreasing pro-inflammatory markers such as interleukin-1 beta (IL-1β). It was primarily investigated for its potential to treat neuroinflammatory and neurodegenerative conditions, including age-related cognitive decline, Alzheimer's disease, and Parkinson's disease. In preclinical models, VP015 demonstrated the ability to restore impaired long-term potentiation (LTP) in the hippocampus of aged or lipopolysaccharide (LPS)-treated rats by promoting a more anti-inflammatory microenvironment.
- Other names
- phospholipid microparticles-incorporating phosphatidylserine
02
Targets
IL1B (Interleukin-1 beta)IL-4 (Interleukin 4)
Beyond the preview
Go deeper on VP015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VP015.